

RS - 34

SECTION Restricted Use	PAGE Page 1 of 1
SUBJECT/TITLE	ORIGINAL DATE 1998-Jul-30
COMBINATION THERAPY OF ANGIOTENSIN RECEPTOR BLOCKERS (ARBs) WITH ACE-INHIBITORS (ACE-Is)	REVISION DATES 2015-Apr-20 2019-Aug-26 2020-Mar-31

PROTOCOLS

ARBs USED IN COMBINATION THERAPY WITH AN ACE-I

1. Congestive Heart Failure

For hypertensive heart failure when blood pressure is not sufficiently controlled, a Formulary ARB may be used with a Formulary ACE-I and other antihypertensive drug treatments when recommended by a cardiologist.

• Ongoing and careful monitoring is recommended due to potential adverse effects such as hypotension, hyperkalemia and worsening renal function. (1)(2)

2. Chronic Kidney Disease

For chronic kidney disease, a Formulary ARB may be used with a Formulary ACE-I when recommended by a nephrologist.

• Ongoing and careful monitoring is recommended due to potential adverse effects such as hypotension, hyperkalemia and worsening renal function. (3)(4)

^{1.} The 2014 Canadian Hypertension Education Program Recommendations for Blood Pressure Measurement, Diagnosis, Assessment of Risk, Prevention and Treatment of Hypertension. Dasgupta K, et al. Canadian Journal of Cardiology, 2014, Vol. 30(5), pp. 485-501.

 ²⁰¹³ ACCF/AHA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology Foundation/American heart Ass. Task Force on Practice Guidelines. Yancy CW, Jessup M, Bozkurt B, et al. J of the American College of Cardiology, 2013, Vol.62(16), pp. e147-e239.
3. KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease. Kidney Disease: Improving Global Outcomes (KDIGO) CKD Work Group. Kidney Inter., Suppl. 2013, Vol. 3, pp. 1-150.

^{4.} Canadian Society of Nephrology Commentary on the DKIGO Clinical Practice Guidelines for CKD Evaluation and Management. National Kidney Foundation, Inc. Am J Kidney Disease, 2015, Vol. 65(2), pp. 177-205.